According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

In a blockbuster pharma merger that shook the global biotech sector, Sanofi announced Friday it has officially completed its ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

Fintel reports that on June 2, 2025, JP Morgan downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Neutral. Analyst Price Forecast Suggests 0.02% Downside As of ...

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to Neutral. Analyst Price Forecast Suggests 0.05% Upside As of June 2, 2025 ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotechnology company specializing in precision therapies for cancer and rare diseases, has been making significant strides in the ...

Nuveen Asset Management LLC increased its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 49.2% in the 4th quarter, according to its most recent Form 13F filing with the ...

CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025 ...